202 related articles for article (PubMed ID: 20227821)
1. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
2. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders.
Chun W; Kim Y; Park SH; Choi SJ
J Clin Neurosci; 2021 Aug; 90():311-316. PubMed ID: 34275568
[TBL] [Abstract][Full Text] [Related]
5. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
6. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
Alshekhlee A; Hussain Z; Sultan B; Katirji B
J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
[TBL] [Abstract][Full Text] [Related]
8. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
9. [Immunoglobulin therapy of neuromuscular diseases].
Schuchardt V
Nervenarzt; 1993 Feb; 64(2):91-7. PubMed ID: 8450900
[TBL] [Abstract][Full Text] [Related]
10. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
[TBL] [Abstract][Full Text] [Related]
11. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.
Donofrio PD; Berger A; Brannagan TH; Bromberg MB; Howard JF; Latov N; Quick A; Tandan R
Muscle Nerve; 2009 Nov; 40(5):890-900. PubMed ID: 19768755
[TBL] [Abstract][Full Text] [Related]
12. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
13. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
14. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
[TBL] [Abstract][Full Text] [Related]
15. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin.
Soueidan SA; Dalakas MC
Pediatr Res; 1993 Jan; 33(1 Suppl):S95-100. PubMed ID: 8433882
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin therapy for neuromuscular disorders.
Ross MA
Semin Neurol; 2007 Sep; 27(4):340-6. PubMed ID: 17701871
[TBL] [Abstract][Full Text] [Related]
17. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
Ferrero B; Durelli L
Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
[TBL] [Abstract][Full Text] [Related]
18. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
[TBL] [Abstract][Full Text] [Related]
20. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Barsheshet A; Marai I; Appel S; Zimlichman E
Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
